NasdaqCM - Delayed Quote • USD
Vistagen Therapeutics, Inc. (VTGN)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 4 | 4 |
| Avg. Estimate | -0.36 | -0.37 | -1.6 | -1.96 |
| Low Estimate | -0.46 | -0.38 | -1.74 | -2.07 |
| High Estimate | -0.27 | -0.36 | -1.46 | -1.82 |
| Year Ago EPS | -1.5 | -1.75 | -8.51 | -1.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 4 | 4 |
| Avg. Estimate | 200k | 410k | 1.06M | 200k |
| Low Estimate | -- | 400k | 870k | -- |
| High Estimate | 410k | 410k | 1.28M | 410k |
| Year Ago Sales | 176k | -- | -- | 1.06M |
| Sales Growth (year/est) | 13.60% | -- | -- | -81.10% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.1 | -1.5 | -0.68 | -0.3 |
| EPS Actual | -1.5 | -1.75 | -0.66 | -0.22 |
| Difference | 0.6 | -0.25 | 0.02 | 0.08 |
| Surprise % | 28.60% | -16.70% | 2.90% | 26.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.36 | -0.37 | -1.6 | -1.96 |
| 7 Days Ago | -0.36 | -0.37 | -1.6 | -1.96 |
| 30 Days Ago | -0.36 | -0.37 | -1.6 | -1.96 |
| 60 Days Ago | -0.36 | -0.37 | -1.6 | -1.96 |
| 90 Days Ago | -0.42 | -0.61 | -1.84 | -2.17 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VTGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 76.00% | -- | -- | 0.80% |
| Next Qtr. | 78.90% | -- | -- | 9.60% |
| Current Year | 81.20% | -- | -- | 4.50% |
| Next Year | -22.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | Jefferies: Hold to Buy | 12/7/2023 |
| Initiated | Stifel: Buy | 11/14/2023 |
| Maintains | Maxim Group: Buy to Buy | 9/5/2023 |
| Upgrade | Maxim Group: Hold to Buy | 8/7/2023 |
Related Tickers
FBIO Fortress Biotech, Inc.
1.8100
+2.26%
VIRI Virios Therapeutics, Inc.
0.4499
-0.02%
CDTX Cidara Therapeutics, Inc.
0.7220
-0.03%
OTLK Outlook Therapeutics, Inc.
8.29
-3.72%
ELEV Elevation Oncology, Inc.
4.0100
-3.14%
SEEL Seelos Therapeutics, Inc.
0.3380
+1.81%
SLN Silence Therapeutics plc
22.02
+2.13%
ATHE Alterity Therapeutics Limited
2.1400
+3.38%
TENX Tenax Therapeutics, Inc.
3.6800
+1.10%
VSTM Verastem, Inc.
10.23
-5.63%